United States· US:50633-230_52bb5505-85d0-256a-e063-6294a90a73a8
DANYELZA
A naxitamab product containing naxitamab, registered in United States by BTG International Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- NAXITAMAB
- Manufacturer
- BTG International Inc.
- Country
- United States (US)
- ATC code
- L01FX21
- ATC class
- Naxitamab
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- August 9, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
160 interactions on record for naxitamab.
Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Naxitamab · interactions on record
160 records
- 28 severe
- 126 moderate
- 6 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01FX21
Naxitamab, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e443d963-b0a6-4065-b03d-7d9c3bc27693 GET /v1/drugs/e443d963-b0a6-4065-b03d-7d9c3bc27693?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "40",
"substance": "NAXITAMAB",
"productndc": "50633-230",
"dosage_form": "INJECTION",
"dea_schedule": null,
"strength_unit": "mg/10mL",
"application_number": "BLA761171",
"marketing_category": "BLA"
}See everything about naxitamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.